Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "Appointed"

235 News Found

Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer
People | March 07, 2024

Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer

Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis


Zydus appoints Punit Patel as President and CEO, Americas
People | October 16, 2023

Zydus appoints Punit Patel as President and CEO, Americas

Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace


Nobel prize 2023 for medicine awarded to Katalin Karikó, Drew Weissman for research on mRNA vaccines to fight Covid-19
News | October 03, 2023

Nobel prize 2023 for medicine awarded to Katalin Karikó, Drew Weissman for research on mRNA vaccines to fight Covid-19

The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19


Advent International announces the completion of the acquision of Suven Pharma
News | September 30, 2023

Advent International announces the completion of the acquision of Suven Pharma

New Board of Directors and management team at Suven Pharma also appointed


Merck and Eisai update on Two Phase 3 Trials Evaluating Keytruda plus Lenima for cell lung cancer
Clinical Trials | September 23, 2023

Merck and Eisai update on Two Phase 3 Trials Evaluating Keytruda plus Lenima for cell lung cancer

The companies will work with investigators to share the results with the scientific community


Cenexi appoints Jim McPherson as CEO
People | September 20, 2023

Cenexi appoints Jim McPherson as CEO

Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK


Amgen settles with FTC over US$28 billion deal
Policy | September 04, 2023

Amgen settles with FTC over US$28 billion deal

Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products